Pioglitazone May Impair L-DOPA Anti-Parkinsonian Efficacy in the MPTP-Lesioned Macaque: Results of a Pilot Study

被引：7

作者：

Huot, Philippe ^{[1
,2
]}

Johnston, Tom H. ^{[1
]}

Fox, Susan H. ^{[1
,2
]}

Brotchie, Jonathan M. ^{[1
]}

机构：

[1] Toronto Western Res Inst, Univ Hlth Network, Toronto, ON, Canada

[2] Toronto Western Hosp, Movement Disorder Clin, Div Neurol, Univ Hlth Network, Toronto, ON M5T 2S8, Canada

来源：

SYNAPSE | 2015年 / 69卷 / 03期

基金：

加拿大健康研究院;

关键词：

L-DOPA; MPTP-lesioned macaque; pioglitazone; ON-time; dyskinesia; ACTIVATED RECEPTOR PPAR; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-LESIONED MACAQUE; GAMMA AGONIST; DISEASE; MODEL; DYSKINESIA; PHARMACOKINETICS; MITONEET; MONKEYS; ALPHA;

D O I：

10.1002/syn.21801

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

In this pilot study, pioglitazone, an agonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ) used in the treatment of diabetes mellitus, was administered to dyskinetic parkinsonian macaques. Pioglitazone alleviated L-DOPA-induced dyskinesia, but impaired L-DOPA anti-parkinsonian efficacy. These results suggest caution when administering pioglitazone to patients with advanced Parkinson's disease. © 2015 Wiley Periodicals, Inc.

引用

页码：99 / 102

页数：4

共 21 条

[1]

Ajjan RA, 2008, EXPERT OPIN DRUG SAF, V7, P367, DOI [10.1517/14740338.7.4.367, 10.1517/14740338.7.4.367 ]

[2] The pharmacokinetics of pioglitazone in patients with impaired renal function [J].

Budde, K ;

Neumayer, HH ;

Fritsche, L ;

Sulowicz, W ;

Stompôr, T ;

Eckland, D .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) :368-374

[3] Nuclear receptors and lipid physiology: Opening the X-files [J].

Chawla, A ;

Repa, JJ ;

Evans, RM ;

Mangelsdorf, DJ .

SCIENCE, 2001, 294 (5548) :1866-1870

[4] Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe [J].

Colca, JR ;

McDonald, WG ;

Waldon, DJ ;

Leone, JW ;

Lull, JM ;

Bannow, CA ;

Lund, ET ;

Mathews, WR .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 286 (02) :E252-E260

[5] Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation [J].

Dehmer, T ;

Heneka, MT ;

Sastre, M ;

Dichgans, J ;

Schulz, JB .

JOURNAL OF NEUROCHEMISTRY, 2004, 88 (02) :494-501

[6] mitoNEET as a novel drug target for mitochondrial dysfunction [J].

Geldenhuys, Werner J. ;

Leeper, Thomas C. ;

Carroll, Richard T. .

DRUG DISCOVERY TODAY, 2014, 19 (10) :1601-1606

[7] Pioglitazone [J].

Gillies, PS ;

Dunn, CJ .

DRUGS, 2000, 60 (02) :333-343

[8] Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR) - α and γ agonist against a rat model of oral dyskinesia [J].

Grover, Sania ;

Kumar, Puneet ;

Singh, Kuldeep ;

Vikram, Vir ;

Budhiraja, R. D. .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2013, 111 :17-23

[9] Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque [J].

Huot, Philippe ;

Johnston, Tom H. ;

Snoeren, Tessa ;

Koprich, James B. ;

Hill, Michael P. ;

Fox, Susan H. ;

Brotchie, Jonathan M. .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2013, 37 (05) :831-838

[10] L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease [J].

Huot, Philippe ;

Johnston, Tom H. ;

Koprich, James B. ;

Fox, Susan H. ;

Brotchie, Jonathan M. .

NEUROPHARMACOLOGY, 2012, 63 (05) :829-836

← 1 2 3 →